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Abstract: One of the main reasons for the high drug attrition rate in oncology is the poor clinical predictive power of 2D cancer cell lines cultures 
in vitro which are the standard assay used as screening assay to select new chemical entities (NKE) with potent anticancer activity. Therefore, 
there is increasing interest in developing 3D in vitro cell culture systems, as a primary screening assays which would represent a biologically 
more relevant assay system, due to similarity to physiological conditions in which tumors growth in living organism. Very important is to develop 
reproducible 3D cell line culture in vitro assays, feasible for the primary screening of NKEs platforms. Within this manuscript we have tested 
small platform of selected benzo[b]thieno, thieno[2,3-b]thiophene, and thieno[3,2-b]thiophene 2-carboxanilides, as well as their cyclic 
derivatives [2,3-c]quinolones, which already showed anti-proliferative activity on other cancer cell lines in 2D system. Platform was tested in 
2D and 3D cancer cell culture assays on three human breast cancer cell lines (SK-BR-3, MDA-MB-231, T-47D). Those cell lines were selected on 
the basis of ability to growth and form cell spheres and also on different sensitivity to chemotherapeutic agents. We used doxorubicin as control 
compound due similar mode of action, (specific intercalation with the DNA double helix), as tested compound probably have. 
 Obtained results in some cases showed significant disagreement, indicating that in early screening selection of active compounds only 
on 2D activity basis we could pick up false positive compounds (active only on 2D cell culture lines and not on 3D cell lines for which it is clamed 
that are more similar to real physiological conditions for tumor growth).  One possibility for obtained discrepancy of results obtained on 2D and 
3D cell cultures could be physico-chemical properties of compounds. Therefore, we analyzed some physico-chemical properties of active 
compounds as chrom logD values and calculated structural parameters: number of hydrogen bond donors and acceptors, calculated logP and 
logD values, molecular weight, ionization constants (pKa), number of aromatic rings, number of rotatable bonds and polar surface area. 
Association of physico-chemical descriptors with observed anti-proliferative activity has been investigated. Basicity, molecular weight and 
number of H-bond donors are found to be main factors contributing to the anti-proliferative effect of investigated compounds for both 2D and 
3D cell cultures. 
 





LMOST all cell-based assays within the pharmaceuti-
cal drug discovery research use the traditional 
approach of screening on two dimensional (2D) cell culture 
models. In 2D culture conditions cells need to adjust to a 
flat and rigid surface that can result in altered cell metabo-
lism and functionality.[1,2] Thus, cellular functions and 
physiological responses that are present in organs are often 
lost in 2D cell cultures which are usual standard for testing 
new chemical entities (NCE). The ability of an in vitro bio-
logical assay to produce reliable information about tested 
NCEs is essential in early drug development because it is a 
base of selection of active compounds for further profiling. 
Loosing cellular and physiological functions in 2D cell 













reliable information about activities of the tested NCE’s, 
which is essential in early phase of drug development. 
Therefore, there is a continuous need for improvement of 
existing in vitro technologies, in order to get more accurate 
and more predictive selection of active compounds based 
on biological data in pre-clinical screening assays. 
 Three-dimensional (3D) cell culture techniques have 
become increasingly popular and are suggested to be bet-
ter models than two-dimensional monolayers due to im-
proved cell-to-cell contact and structures that resemble in 
vivo architecture.[3] Cell shape and contacts between cells 
influence the cytoskeleton which can regulate gene and 
protein expression and hence cell function.[4,5] Once expen-
sive, laborious and difficult to be used for screening of 
numerous novel chemical entities, 3D spheroid cultures 
technique is today applicable for both basic research and 
high-throughput screening (HTS). Hanging drop method is 
one of the most well characterised models for 3D culture. 
In our research we have used 3D Biomatrix hanging drop 
plates (http://3dbiomatrix.com/) because they support 
growing of 3D cell culture on a larger scale and also high-
throughput screening of NCE. They support production of 
3D cell cultures of broad range of different cell lines, and 
enable produced 3D cultures to be tested in a high-
throughput manner.[6] Also, because it is a scaffold free 
system, they eliminate the possibility of interaction of the 
NCE with scaffold material. 
 In a recently published paper we recognized differ-
ent drug sensitivity properties of some breast and pancreas 
cancer cell lines, if growing in 2D and 3D conditions. Also, 
activity of some amidino substituted benzimidazole and 
benzimidazo[1,2-a]quinoline derivatives tested on 2D and 
3D cancer cell assay was different. In general, IC50 values 
from 3D assay were higher in comparison with IC50 values 
obtained in 2D cell model papers.[7] Because the 2D cancer 
cell line cultures in vitro are still standard assay used for 
selection of active compounds with anti-proliferative activ-
ity, it is important to compare activity of compounds in 2D 
and 3D cell culture systems. Previously obtained significant 
disagreement in IC50 values for tested compounds indicate 
that in early screening selection of active compounds only 
on 2D activity basis we could pick up false positive 
compounds which are active only on 2D cell culture lines 
and not on 3D cell lines for which it is clamed that are more 
similar to real physiological conditions for tumor growth. 
 In this paper we analysed physicochemical proper-
ties of tested compounds as possible reason for different 
activity. It was showed that penetration of compounds  
is more difficult in compounds that growth in spherical  
way in comparison with cells in monolayer.[8] Also, due to 
assay validation assay quality parameters (Z’ and signal to 
background, S:B) for both 2D and 3D cell assays were 
analysed. 
 Over the past few years substituted nitrogen and sul-
phur heterocycles have been one of the most extensively 
studied classes of organic compounds due to their well-
known biological activities and thus, they play an extremely 
important role in medicinal chemistry.[9] More specifically, 
substituted heterocyclic benzo[b]thiophenes, quinolones 
and carboxamides as very important organic structural 
motifs, have therefore recently attracted considerable 
attention from medicinal and synthetic organic chemists 
due to their spectra of diverse pharmacological features.[10–
13] Furthermore, abovementioned structural units could be 
found in a variety of bioactive natural products and numer-
ous of synthetic medical and biochemical agents. As a part 
of our continuing search for potential anticancer agents 
structurally related to heterocyclic quinolones, we have 
previously reported synthesis and strong inhibitory activi-
ties on several human tumor cell lines of versatile benzothi-
ophene and thienothiophene carboxanilides and 
quinolones, thus confirming the anticancer potential of this 
class of compounds.[14–17] 
 In general, amidino-substituted benzo[b]thieno[2,3-
c]quinolones, strong ds-DNA/RNA intercalators, showed in 
general stronger and more selective antitumor activity than 
acyclic precursors. Also, we have shown that replacement 
of the acyclic amidino groups with cyclic amidino 2-imidaz-
olinyl group, respectively, resulted with increased anti-
tumor activity. Furthermore, compounds with high DNA 
binding capacity were identified as the most promising 
inhibitors of tumor growth and of topoisomerase 
activity.[14–17] 
 Guided by all above mentioned compounds, we have 
chosen selected benzo[b]thiophene, thieno[2,3-b]thio-
phene and thieno[3,2-b]thiophene-2-carboxanilides and 
their cyclic derivatives [2,3-c]quinolones as potential anti-
cancer agents for further biological evaluation. The 
screened compounds were used as a small platform to 
compare potential antitumor activity in 2D and 3D cancer 
cell culture system. Our goal was to compare the drug sen-
sitivities of the three human breast cancer cell lines (SK-BR-
3, MDA-MB-231, T-47D) grown in 2D and 3D cell culture 
conditions, and test the hypothesis about differences in ac-
tivities of chemotherapeutic drugs in 2D and 3D assays.[18] 
 Physicochemical properties of tested compounds 
have been studied using chromatographic lipophilicity 
measure, chrom logD, and calculated structural parame-
ters: number of hydrogen bond donors and acceptors, cal-
culated logP and logD values, molecular weight, ionization 
constants (pKa), number of aromatic rings, number of rotat-
able bonds and polar surface area. 
 The importance of physicochemical properties of 
compounds at early stage of discovery of new drugs is now 
well established. Among these properties, lipophilicity rep-
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relationship between compounds with anticancer activity 
and lipophilicity has been investigated for different classes 
of compounds.[19–21] Lipophilicity measurements by reverse 
phase chromatography have been already proven as fast 
and efficient method for compound profiling in the early 
phase of optimization and results are expressed as Chroma-
tographic logD (chrom logD).[22–24] Association of physico-
chemical and structural parameters with observed anti-
proliferative activity was studied with multivariate statisti-
cal methods. Classification models for anti-proliferative 
activity in 2D cell lines were successfully developed and 
structural contributions to biological activity have been 
discussed. 
 
MATERIALS AND METHODS 
Chemistry 
The benzo[b]thieno, thieno[2,3-b]thiophene and thieno[3,2-b]-
thiophene 2-carboxanilide compounds 1–20 (Figure 1a) and 
their cyclic derivatives [2,3-c]quinolones 21–40 (Figure 1b) 
were previously synthesized and characterized in our 
research group.[14–16] 
 Starting from corresponding carbonyl-chlorides and 
substituted anilines, 2-carboxanilides 1–5, 7 and 18–19 
were prepared. Amidino substituted derivatives 1–4 and 
14–17 were prepared by Pinner reaction from cyano sub-
stituted precursors. Quaternary ammonium salts 8–9, 20 
and 29–31 were prepared with the excess of HCl(g) or 
methyl-iodide while amino substituted derivative 6 was 
prepared by reduction of nitro analogues and 28 by acidic 
hydrolysis of 32. Cyclic derivatives [2,3-c]quinolones, 21–
22, 25, 27, 32–38 and 40 obtained by photochemical cy-
clization from acyclic precursors. N-alkylated derivatives 
23–24, 30–31 and 39 were synthesized due to the alkyla-
tion with methyl-iodide. Acyclic compounds bearing N,N-
dimethyaminopropyl-amide side chain on phenyl ring 10–
13 were prepared in the reaction with N,N-dimethyamino-
1-propylamine which gave in the photochemical cyclization 
substituted [2,3-b]quinolones 34–37. 
 
SYNTHESIS 
The synthesis and spectroscopic characterization of com-
pounds 1–40 was previously published in our research 
group.[14–17] 
 
CHROM logD DETERMINATION 
Chrom logD values were determined from the following 
equation: chrom logD = 0.0857 x CHI – 2 (ref. Chromato-
graphic Hydrophobic Index (CHI) values have been deter-
mined from gradient retention times (tR) as described by 
Valkó and Slegel.[25] These values approximately corre-
spond to the volume percentage of organic component in 
the mobile phase when the compound elutes. CHI values 
were determined at pH 2.7 and 7.4. Chromatograms were 
obtained using an Agilent 1100 Series HPLC instruments 
equipped with diode array detector (DAD) coupled with 
Micromass Quattro API mass spectrometer. Data acquisition 
 
 
Figure 1. a) Structures of benzo[b]thieno-, thieno[2,3-b]thiophene- and thieno[3,2-b]thiophene 2-carboxanilides 1–20. b) 












and processing were performed with MassLynx software ver-
sion 4.1. The column used for CHI determination was Luna 
C18 (50mm × 3 mm i.d., 5 µm particle size, 100 Å). The aque-
ous part of the mobile phase was 50mM ammonium acetate 
adjusted with ammonia solution to pH 7.4 and 0.1 % (v / v) 
formic acid in water for pH 2.7. As an organic part of their 
mobile phase acetonitrile was used. The mobile phase flow 
rate was 1 mL min–1 for all measurements. The gradient re-
tention times tR were measured under the following gradient 
condition: 0 to 3 min linear gradient from 0 to 100 % acetoni-
trile; 3 to 3.5 min 100 % acetonitrile; 3.5 to 3.7 min from  
100 to 0 % acetonitrile; and 3.7 to 5 min re-equilibration time 
with 100 % of aqueous part of the mobile phase. 
Antitumor Activity Assays 
To compare the difference in compound anti-proliferative 
activity we have tested 40 benzo[b]thieno, thieno[2,3-
b]thiophene and thieno[3,2-b]thiophene 2-carboxanilides 
and their cyclic derivatives [2,3-c]quinolones in 2D and 3D 
cell assays. Control compound in both assays was doxoru-
bicin, an anthracycline antibiotic that intercalate into DNA 
double helical structure. 
 For 2D cell assay we used traditional two-dimen-
sional in vitro cancer cell line proliferation assay, one of the 
most widely used assay for evaluating preliminary anti-
cancer activity of new chemical entities (NCE). As a 3D assay 
we used hanging drop proliferation cell assay. 
 
CELL CULTURES 
Human breast cancer cell lines SK-BR-3 (HTB-30), MDA-MB-
231 (HTB-26) and T-47D (HTB-133) were purchased from 
ATCC and were maintained in appropriated, recommended 
manner by using supplier medium, supplemented with  
10 % heat inactivated fetal bovine serum and penicillin / 
streptomycin / amphotericin B, in a humidified atmosphere 
of 5 % CO2 and 95 % O2 at 37 °C. 
 
TEST COMPOUNDS AND STANDARD COMPOUND 
Doxorubicin was purchased from Apollo (BID0120; Opelika, 
AL). Test compounds were synthesized by research group 
at Department of Organic Chemistry, Faculty of Chemical 
Engineering and Technology, University of Zagreb. 
 Mother plates (96-well-V plates, polypropylene, 
Greiner Bio-one, Cat. 651201) with serial dilutions of com-
pounds in pure DMSO are prepared from 10 mM DMSO 
stock solutions on Janus automatic pipetting workstation 
(Perkin-Elmer). Compounds were diluted 1 : 3. 300 nL of 
compound were transferred from mother plate to test 
plate by using Mosquito (TTP labtech). DMSO percentage in 
test concentrations was 0.3 %. Final starting concentration 
of the standard compound and test compounds was 30 µM 
(other concentrations were: 10 µM, 3.33 µM, 1.11 µM,  
0.37 µM, 0.12 µM, 0.04 µM and 0.014 µM). 
2D AND 3D DRUG SCREENING SETUP 
To determine the influence of testing compounds on the 
cell viability drug sensitivity testing was performed in 2D 
and in 3D cell culture format. 2D and 3D drug screening 
setup was done as published before.[7] In brief, for 2D 
cell culture assay, cells were grown in 96-well cell star 
polystyrene plates, by using 10 000 cells per well, 
seeded 4 h prior the treatment with different 
compounds concentrations and incubated for 72 h. For 
3D cell culture assay, cells were grown in 96-well 
Perfecta 3D hanging drop plates, by using 5000 cells per 
well, seeded and incubated 4 days, until spheres were 
formed (checked under the microscope). After sphere 
formation, cells were treated with compounds followed 
by 72 h incubation. 
 A cell viability assay was performed according to 
the manufacturer’s instruction, using CellTiter® 96 
Aqueous One Solution Cell Proliferation Assay, MTS kit, 
(Promega, Madison, WI). After 0.5–2 h of cell incubation 
with MTS, the plates were read using Perkin Elmer® 
EnVision 2104 at 490 nm. The results for each of tested 
compounds are reported as growth percentages from 
three independent concentrations curves compared with 
the untreated control cells after drug exposure. 
 
STATISTICAL ANALYSIS 
Calculation of IC50 data, curves and QC analysis is made by 
using Excel tools and GraphPadPrism software (La Jolla, 
CA), v. 5.03. In brief, individual concentration–effect curves 
are generated by plotting the logarithm of the tested con-
centration of tested compounds (X) versus corresponding 
percent inhibition values (Y) using least squares (ordinary) 
fit. Best fit IC50 values are calculated using Log(inhibitor) 
versus normalized response – Variable slope equation, 
where Y = 100 / (1 + 10((logIC50 – X) * HillSlope)). QC criteria 




Computational analysis of biological results has been 
performed using Vortex and Simca software’s (v. P-11, 
Malmo, Sweden) from Umetrics. Simple structural 
parameters were calculated using ACD / Percepta software 
(v. 2015, Toronto, ON) from ACD / Labs; molecular weight, 
clogP, clogD, number of hydrogen bond acceptors and 
number of hydrogen bond donors, number of aromatic 
rings, number of halogen atoms and pKa. Principal 
component analysis (PCA), partial least square analysis 
(PLS) and partial least square discriminant analysis has been 
used to build a statistical models for 2D and 3D anti-
proliferative effect. Field based alignment has been 
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RESULTS AND DISCUSSION 
Spherical Growth of Breast Cancer Cell 
Lines in 3D Conditions 
To prove that selected breast cancer cell lines can form 
spheres or growth in spherical manner in 3D conditions we 
followed the growth of each during 6 days from cells 
seeding. Formation of spherical growth of MDA-MB-231, 
SK-BR-3 and T-47D cells in 3D format during period of 6 
days (4-5x magnification, seeding density 5000 cells / well) 
are presented on Figure 2. From obtained results we 
concluded that for all three cell lines on day 4 from cell 
seeding treatment with compounds can started. 
Differences in Drug Responses Between 
2D and 3D Culture Models 
 
Antitumor activity of compounds 1–40 were tested in 2D 
and 3D cell cultures. As control or standard compound we 
use doxorubicin due to similar mode of action to tested 
compounds[26]. In this set up of assays, doxorubicin showed 
higher IC50 values in 3D assays on all three cell lines (for 
MDA-MB-231 0.23 ± 0.07 µM; SK-BR-3 1.29 ± 0.16 µM; and 
T-47D 1.01±0.13 µM) compared to IC50 values in 2D assays 
(for MDA-MB-231 0.16 ± 0.07 µM; SK-BR-3 0.1 ± 0.02 µM; 
and T-47D 0.08 ± 0.01 µM). However, on MDA-MB-231 cell 
line IC50 value of doxorubicin were only slightly higher in 3D 
assay when compared with IC50 obtained in 2D assay 
(Figure 3 / Table 1). 
 The highest discrepancy of IC50 values for 
doxorubicin was obtained on T47D cell line (0.08 ± 0.01 µM 
in 2D and 1.01 ± 0.13 µM in 3D). Therefore, we concluded 
that MDA-MB-231 cell line is most susceptible and the 
T47D cell line more resistant in comparison with other two. 
For doxorubicin the obtained IC50 values in 2D assay were 
comparable with IC50 values found in the literature,[27–29] 
taking in account the differences in assay setup (number of 
cells per well, cell line sensitivity, source and formulation of 
tested standard drugs, washout period, cell passage 
number, etc.). Related to 3D assay, IC50 values in a 3D cell 
culture models depends, besides all other known factors,  
 
 
Figure 2. Formation of spherical growth of MDA-MB-231 
(up), SK-BR-3 (middle) and T-47D (down) cells in 3D format 
during period of 6 days (4-5x magnification, seeding density 
5000 cells / well).[32] 
 
 
Figure 3. Doxorubicin dose-response profiles obtained on 
2D and 3D cell culture assay of MDA-MB-231, SK-BR-3 and 













Table 1. Antitumor activity of compounds 1-40 and control compound (Doxorubicin) in 2D and 3D cell cultures (MDA-MB-231, 
SK-BR-3 and T-47D breast cancer cell lines), after 72 h of incubation with tested compounds.. 
Cpd 
IC50 / µM ± SD; N = 3 
MDA-MB-231 SK-BR-3 T47D 
2D 3D 2D 3D 2D 3D 
1 5±0.56 2±0.22 3±0.16 21 5±0.14 18±3.17 
2 9±0.06 3±0.58 5±0.05 >30 7±0.4 20±3.70 
3 11±1.64 16±0.56 10±0.31 >30 16±0.41 >30 
4 10±0.09 15±0.50 13±0.74 >30 18±0.54 >30 
5 >30 >30 >30 >30 >30 >30 
6 >30 >30 >30 >30 >30 >30 
7 >30 >30 >30 >30 >30 >30 
8 >30 >30 >30 >30 >30 >30 
9 >30 >30 >30 >30 >30 >30 
10 9±0.10 14±1.9 11±0.44 >30 14±0.15 >30 
11 2±0.40 12.5±0.9 0.96±0.16 >30 5±0.66 >30 
12 6±1.91 21±4.1 4±0.05 27±0.41 5±0.85 >30 
13 5±0.29 >30 4±0.3 >30 4±0.46 >30 
14 5±0.12 3±0.03 5±0.12 >30 5±0.25 13±2.00 
15 12±0.13 8±2.56 15±0.38 >30 13±1.43 >30 
16 12±0.30 17±0.88 17±0.84 >30 13±0.3 >30 
17 12±0.08 15±0.79 15±0.34 >30 24±0.4 >30 
18 >30 >30 0.34±0.16 >30 >30 >30 
19 >30 >30 0.43±0.18 >30 >30 >30 
20 >30 >30 1.08±0.33 >30 >30 >30 
21 2±0.10 2±0.20 4±0.23 26 6±0.62 >30 
22 4±0.37 7±0.90 5±0.12 22 14±0.27 >30 
23 3±0.81 3±0.83 3±0.47 19 5±0.22 18±5.20 
24 4±0.85 2±0.43 4±0.10 >30 6±0.1 16±4.20 
25 11±0.38 >30 8±0.45 >30 18±0.09 >30 
26 12±2.10 >30 4±0.17 >30 12±0.37 >30 
27 >30 >30 0.34±0.19 >30 >30 >30 
28 11±0.64 4.8±0.84 7±0.16 >30 >30 >30 
29 >30 >30 >30 >30 >30 >30 
30 >30 6.95±1.3 >30 >30 >30 >30 
31 >30 >30 >30 >30 >30 >30 
32 >30 >30 0.78±0.28 >30 >30 >30 
33 1±0.22 20±1.71 4±0.18 >30 >30 >30 
34 11±1.69 15±1.16 9±1.15 >30 14±1.33 >30 
35 10±0.31 25±0.53 6±0.31 >30 14±0.44 >30 
36 2±0.44 12±0.63 3±0.13 >30 6±2.21 >30 
37 3±0.14 >30 7±1.78 >30 >30 >30 
38 4±0.05 14±4.5 6±0.26 29 12±0.23 >30 
39 3±0.56 6±2.17 5±0.03 >30 8±0.63 >30 
40 >30 >30 >30 >30 >30 >30 
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on spheroid growth and/or forming of sphere. As is showed 
on Figure 2, MDA-MB-231 and SK-BR-3 growth has an 
spherical shape, but T-47D forms spheres with basal 
membrane around it, and this can have an impact on IC50 
values discrepancy. Quality parameters for 2D and 3D 
assays (Z’ and S : B) were within standard expected values 
for all three cell lines. Standard Z’ for cell in vitro assays 
from 0.35 to1, signal to background > 1.5 and hillslope 
between 0.5 and 5. 
 For tested compounds, we obtained the variations in 
responses in 2D and 3D cell culture system for all three 
breast cancer cell lines (Table 1). In general, IC50 values 
from 3D assay were higher in comparison with IC50 values 
obtained in 2D cell model, which means that compounds 
were less active in 3D cellular assay models. Exceptions 
were only compounds 15, 28 and 30 on MDA-MB-231 cell 
line. Eight compounds were highly active in both 2D and 3D 
test formats (1, 2, 14, 21, 22, 23, 24, 39), but only on MDA-
MB-231 cell line. However, none of these compounds 
showed such a profile on SK-BR-3 and T47D cell lines. Most 
of the compounds were highly active in 2D format assay, 
but in 3D format assay the same compounds showed mod-
erate or no activity. Such activity pattern was observed for 
12 compounds on MDA- MA-231 (3, 4, 10, 11, 12, 13, 25, 
33, 36, 37, 38, 39), 25 compounds on SK-BR-3 cell line (1, 
2,11 ,12, 13, 14, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 
32, 33, 34, 35, 36, 37, 38, 39) and 11 compounds on T47D 
cell line (1, 2, 11, 12, 13, 14, 21 ,23, 24, 36 39). Compounds 
11, 12 and 13 were active on all three cell lines in 2D format 
assay. 
 In general, there was poor or no trend between IC50 
values on 2D and 3D assays format suggesting that 3D assay 
provided different potency information in comparison with 
2D assay. On Figure 4 IC50 values (dots) of 40 NCEs in 2D and 
3D format cell culture assay on MDA-MB-231, SK-BR-3 and 
T-47D cells are presented. If we compare number of active 
compounds on each cell lines in both assay formats, the 
most of the compounds showed significant activity on 
MDA-MB-231 cell line, and lower activity profile on SK-BR 
and T47D cell lines which is in line with cell line susceptibil-
ity / resistance. Statistical correlation of compounds IC50 
values on 2D and 3D assays format is presented in Table 2. 
The best correlation between IC50 values on 2D and 3D 
assays format is on MDA –MB-231 cell line (0.666) than for 
T47D (0.501) and then for SK-Br-3 (0.274). 
Structure-Activity Relationship (SAR) in 
2D Assays 
The results obtained from the evaluation of antitumor 
activity in the 2D assays revealed that some of tested com-
pounds showed very pronounced selective activity in 
submicromolar concentrations range on SK-BR-3 cell lines. 
Among acyclic derivatives, compounds showed to be the 
most selective and active were thieno[2,3-b]thiophene-2-
carboxamides bearing nitro (18, IC50 = 0.34 µM), N,N-
dimethylamino (19, IC50 = 0.43 µM) and protonated N,N-
dimethylamino group (20, IC50 = 1.08 µM), and nitro substi-
tuted benzo[b]thieno-2-carboxamide bearing amide side 
chain (11, IC50 = 0.96 µM). Furthermore, the same 
Table 2. Correlation between collected biological data (anti-
proliferative activity for 40 compounds, 2D vs. 3D). 
















MB-231  0.6 0.801 0.666 0.374 0.337 
2D SK-BR-3 0.6  0.52 0.334 0.274 0.26 
2D T-47D 0.801 0.52  0.662 0.439 0.501 
3D MDA-
MB-231 
0.666 0.334 0.662  0.521 0.588 
3D SK-BR-3 0.374 0.274 0.439 0.521  0.549 




Figure 4. Correlation of IC50 values obtained in 2D and 3D assay format for three breast cancer cell lines MDA-MB-231 (left), SK-












selectivity and activity was also displayed by cyclic nitro (27, 
IC50 = 0.34 µM) and N-acetamido (32, IC50 = 0.78 µM) sub-
stituted benzo[b]thieno[2,3-c]quinolones. In general, both 
acyclic and cyclic amidino substituted 2-carboxamides and 
quinolones bearing cyclic 2-imidazolinyl amidine group 1–
2, 14–15, 21–24 and 38–39 were more active in comparison 
with the same analogues bearing isopropylamidine group 
3–4, 16–17, 25–26 and 40. This was in good agreement with 
our previous presumption that replacement of the acyclic 
amidino groups with cyclic amidino 2-imidazolinyl group, 
respectively, resulted with increased antitumor activity. 
Also, N-methylation of cyclic 2-imidazolinyl substituted 
derivatives 23–24 and 39 slightly increased the antitumor 
activity. In general, translation of the amidino groups from 
the anilide or quinolone to benzo[b]thiophene part of the 
molecule did not significantly influence the activity. Amino 
substituted benzo[b]thieno[2,3-c]quinolone 28 showed the 
increased activity on MDA-MB-231 cell line in comparison 
to the nitro analogue 27. Compared to N-acetamido cyclic 
derivative 32, N-alkylated N-acetamido cyclic derivative 33, 
as the most active one among all tested compounds, 
showed significant decrease of activity on SK-BR-3 cell line, 
as well as improved activity on MDA-MB-231 cell line. 
Moreover, benzo[b]thieno-2-carboxanilides substituted 
with nitrogen-bearing substituents 5–9 together with cyclic 
benzo[b]thiophenes prepared as quaternary ammonium 
salts 29–31 and isopropyl-amido substituted thieno[2,3-
b]thieno[2,3-c]quinolone 40 were inactive against all can-
cer cell lines. 
 Since some of investigated compounds were charac-
terised as DNA intercalators,[14–17] due to their characteris-
tic structural features containing flat aromatic regions as 
well as positively charged basic centre, field based overlay 
and comparison of daunorubicin complex with DNA and 
some of the most potent compounds have been performed 
(Figure 5). Molecular field technology is particularly useful 
for comparison of diverse chemotypes with analogous 
mode of action and provide a way to understand how the 
surface properties of molecules with underlying atomic 
structure can be translated into biologically relevant bind-
ing properties.[30] 
 Figure 5a displays molecular field distribution for 
daunorubicin in bioactive conformation and compound 36. 
Both compounds are characterised with polarisation of 
electrostatic contributions with red being positive potential 
and blue negative. Hydrophobic aromatic core, shown in 
yellow is placed in between these regions. 
 Although structural similarity for the whole molecule 
is not high, major structural features do overlap and molec-
ular field similarity is much higher indicating possible anal-
ogous binding mode. Field overlap analysis indicates that 
further structural optimisations might introduce a spacer 
between cyclic 2-imidazolinyl amidine group and acyclic 
and cyclic amidino substituted 2-carboxamides and quin-
olones improving alignment of pharmacophoric features. 
 
Structure-Activity Relationship (SAR) in 
3D Assays 
As it can be viewed from the Table 1, results obtained from 
the evaluation of antitumor activity in the 3D cell culture 
systems indicated the selective activity of some tested 
compounds on MDA-MB-231 cell line. The most active 
compounds among all tested showed to be acyclic (1) and 
cyclic (21) benzo[b]thiophene derivatives bearing 2-imidaz-
olinyl group at the anilide and quinolone part of the mole-
cule, with IC50 = 2.0 µM. In addition, isopropyl-amidino 
 
Figure 5. a) Molecular field overlay of compound 36 with 
daunorubicin. Structure of daunorubicin is taken from its 
complex with DNA (pdb : ID11). Positive electrostatic 
potential is shown in red, negative electrostatic potential is 
shown in blue and hydrophobic regions are shown in yellow; 
b) Field-based alignment of bioactive conformation for 
daunorubicin (magenta) in complex with DNA (shown as a 
surface color coded by electrostatic potential with acidic 
regions as red and basic regions as blue) and compound 36 
(in green); c) Field-based alignment of compound 2 (green) 
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substituted derivatives, both acyclic (3–4 and 16–17) and 
cyclic (25–26 and 40), were less active than 2-imidazolinyl 
substituted derivatives as it was expected. 2-imidazolinyl 
substituted thieno[2,3-b]thiophene-2-carboxamides 14 
and 15 showed also pronounced activity slightly decrease 
in comparison to their benzo[b]thiophene analogues. 
Furthermore, moderate activity on MDA-MB-231 cell line 
was observed with compounds bearing N,N-dimethyl- 
amino-1-propyl amide side chain on anilide (10–13) and 
quinolone (34–36) part of the molecule with the exception 
of methyl substituted cyclic derivative 40 which was 
inactive. Benzo[b]thiophene-2-carboxanilides 5–9 and 
thieno[2,3-b]thiophene-2-carboxanilides 18–20, as well as 
benzo[b]thieno[2,3-c]quinolones 27, 29 and 31–32, substi-
tuted with nitrogen-bearing substituents, were inactive on 
all tested cell lines. Cyclic derivatives bearing amino group 
(28) and protonated N,N-dimethylamino group (30) also 
showed very pronounced antitumor activity on the same 
cell line. Compounds bearing 2-imidazolinyl substituent 
either on anilide (1–2 and 14) or quinolone part of the mol-
ecule (23–24) displayed also moderate activity on T-47D 
cell line as well as on SK-BR-3 cell line (1, 21–23 and 38). 
Influence of Physico-Chemical 
Properties on Anti-Proliferative Activity 
in 2D and 3D Cell Culture Assay 
Anti-proliferative activity for 40 compounds (2D vs. 3D) has 
been analysed in terms of measured and calculated 
lipophilicity values and number of simple 2D descriptors 
describing structural variations among the current data set. 
 Anti-proliferative activity on MDA-MB-231 (2D) cells 
correlates well with T-47D (2D) (r = 0.8) and somewhat less 
with SK-BR-3 (2D) (r = 0.6). Correlation between 2D and 3D 
cells is weaker, that might be a result of lower cell 
permeation in 3D cultures resulting in shift of activity 
distribution toward higher IC50 values. Inter-correlation 
between collected biological data is shown in Table 2. 
Antiproliferative activity measured for the MDA-MB-321 
(2D) cells correlate best with other cell types. The MDA-
MB-321 (2D) cells are also most sensitive ones. Therefore, 
more detailed analysis for this particular cell type has been 
performed. 
 As an initial attempt to rationalise SAR of antitumor 
activity for benzothiophene and thienothiophene 
carboxanilides and quinolones in a semi-quantitative, and 
possibly predictive way, influence of physicochemical and 
structural properties on anti-proliferative activity has been 
investigated. As an experimental measure of lipophilicity, 
chromLogD values (Table 3) were used together with a 
number of calculated structural descriptors: molecular 
weight, clogP, clogD, number of hydrogen bond acceptors 
and number of hydrogen bond donors, number of aromatic 
rings, number of halogen atoms and pKa. 
 Principal component analysis of biological data and 
calculated structural descriptors has been done. Loading 
plot shows grouping of 2D and 3D IC50 values; grouping of 
lipophilicity descriptors, reflecting the consistency between 
calculated and experimentally obtained ones as well as 
clustering of basicity and polarity descriptors. Score plot, 
indicates that compound data points are well distributed 
using calculated and measured descriptors (Figure 6). 
 Partial least square discriminant analysis (PLS_DA) 
has been applied in order to build QSAR models for anti-
proliferative activity data. Classification approach has been 
selected based on the semi-quantitative nature of 
measured biological data. In case of MDA-MB-231 cells, 26 
compounds with IC50 less than 12µM are treated as active 
(class1) and 14 compounds with IC50 greater than 30 M are 
treated as not active. 35 compounds were used in the 
training set and 5 compounds were defined as a small 
validation set. PLS-DA model is shown on Figure 7. 
Table 3. Chrom logD values determined from the following 
equation: chrom logD = 0.0857 × CHI – 2. Chromatographic 
Hydrophobic Index (CHI) values have been determined from 
gradient retention times (tR) at pH 7.4 and pH 2.7. Values for 
compounds 15 and 30 were not determined, due to lack of 










1 2.99 1.35  21 1.48 0.40 
2 2.71 1.16  22 1.07 0.10 
3 3.44 1.39  23 2.05 0.74 
4 3.07 1.39  24 1.81 0.57 
5 7.28 7.34  25 1.81 0.61 
6 5.11 7.15  26 1.44 0.36 
7 7.40 5.31  27 5.24 5.31 
8 7.40 5.31  28 2.71 1.29 
9 2.79 1.24  29 1.20 0.10 
10 3.03 1.43  30 ND ND 
11 3.07 1.50  31 1.77 0.48 
12 3.93 2.01  32 2.75 2.77 
13 3.56 1.79  33 2.09 0.80 
14 2.67 1.16  34 2.99 1.43 
15 ND ND  35 2.99 5.69 
16 3.11 1.37  36 2.30 0.99 
17 3.11 1.46  37 1.89 0.74 
18 6.99 7.08  38 1.24 0.19 
19 7.11 4.52  39 1.77 0.53 













 Very good separation of two defined classes has 
been obtained with only 2 compounds out of 40 
misclassified. It would be useful to repeat biological test for 
this two compounds as they are both structurally more 
similar to the compounds in the predicted classes. First 
compound is 40, predicted to be active and experimentally 
determined to be non-active. Compound 40 is carrying 
acetamidine group which adds to activity on structurally 
similar compounds 25 and 26. Second compound is 28, 
predicted to be non-active, experimentally being active, 
while its closest structural analogues are non-active. This 
discrepancy between calculated and experimental data 
might also be result of some specific target based 
interactions which cannot be deconvoluted from the 
current data set. Five compounds in the validation set, 1, 7, 
31, 37 and 39, have all been properly classified; three of 
them being active and two non-active (Table 4). 
 Descriptor contributions to the PLS-DA model are 
shown on Figure 7c as coefficients to the models for Class1 
and Class2. Inverse contributions are observed for these 
two classes, as expected. Basicity, molecular weight and 
number of H-bond donors are main factors contributing to 
the activity of investigated compounds.  These three 
descriptors account for a combined effect of specific 
interactions with biological target, presumably DNA 
unwinding and intercalation as discussed in section 
Structure-activity relationship (SAR) in 2D assays, as well as 
increase in permeability resulting in the activity of 
compound. Chrom logD and number of halogen atoms are 
positively related to lack of activity of compounds. This 
result might also be a consequence of the property 
distribution of the current data set and the fact that chrom 
logD is a combined measure of lipophilicity and ionizability 
of the compounds. 
 Since measured anti-proliferative activity is complex 
phenomena consisting of, at least, two major parameters; 
permeability and uptake into cells as well as interaction 
with biological target(s), larger data set is needed to 
deconvolute these two phenomena and to determine 
preferable property ranges. We showed previously on a 
different set of compounds that uptake into cells is mainly 
governed by lipophilicity and basicity of compounds.[31] 
 Statistical models for the 3D cells are in general 
somewhat less accurate with similar descriptor 
contribution. Weaker ability to distinguish between active 
and non-active compounds indicates some additional 
underlying features that also play important role in anti-
proliferative activity on the 3D cell, but were not used in 
 
 
Figure 6. a) PCA loadings and b) scores of the first two 
components for the biological and structural data. 
 
 
Figure 7. PLS-DA model (class1 –active, class2-in-active) for 
2D MDA-MB-231 cell data: a) statistical parameters,  
calculated vs. b) experimental data and c) descriptor 
coefficients. 
 






Pred_Class2 IC50 / µM 
1 0.80 0.19 5.4 
7 0.03 0.96 30 
31 -0.09 1.09 30 
37 0.95 0.04 3.5 
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the current study. Inverted contribution of HBDs for 3D 
assay in comparison with 2D assay supports assumption of 
different membrane permeability for 2D and 3D assays but 
this differential behaviour needs further investigation. 
 
CONCLUSIONS 
We compared the drug activity of 40 benzo[b]thieno, 
thieno[2,3-b]thiophene and thieno[3,2-b]thiophene-2-
carboxanilides, and [2,3-c]quinolone compounds on the 
three human breast cancer cell lines (SK-BR-3, MDA-MB-
231, T-47D) grown in 2D and 3D cell culture conditions. All 
three cell lines forms optimal tumor spheres 4 days after 
seeding of the cells in 3D culture plate. Doxorubicin, used 
as a standard drug, showed higher IC50 values in 3D cell 
culture format assay, in comparison with 2D, in all three cell 
lines. In general, 40 tested NCEs showed higher IC50 values 
in 3D format assay than in 2D in all three cell lines. Although 
biological significance of obtained data is still poorly 
understood, discrepancy of IC50 values illustrated 
importance of implementation of 3D cell culture assays in 
early screening cascade. Assay quality parameters (Z’ and 
S:B) were high and reproducible, both for 2D and 3D cell 
assays. For these compounds, experimental lipophilicity, as 
determined by RP-HPLC was expressed by using chrom 
logD. These values were in the range 1.07–7.40 at pH 7.4 
and between 0.10–7.34 at pH 2.7. Physico-chemical 
properties of investigated compounds have been studied in 
terms of lipophilicity expressed as chrom logD values and 
calculated structural parameters: number of hydrogen 
bond donors and acceptors, calculated logP and logD 
values, molecular weight, ionization constants (pKa). PLS-
DA model has been developed with good classification 
power, distinguishing active from non-active compounds in 
2D assay. Basicity, molecular weight and number of H-bond 
donors are main factors contributing to the anti-
proliferative effect of investigated compounds. Simple 
structural and physico-chemical parameters identified in 
the current study can be used as a useful tool, in the early 
phases of the research, to design, filter and prioritize 
compounds for synthesis and screening for anti-
proliferative activity. They can also serve as a sound basis 
for further, more detailed investigation of differential 
activity in 2D and 3D cells. 
 To prove scientific relevance of compound activities 
obtained in 3D cell cancer cell lines in vitro it is necessary to 
tested active compounds in animal cancer models. 
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